Important note: Information in this article was accurate in 2000. The state of the art may have changed since the publication date.
PRNewswire - Monday November 27, 2000
More than 95% of the global burden of HIV has been assumed by the nations least equipped to deal with the costs of combating the disease. In many regions, the inherent nature of the epidemic is very different from that experienced in the developed world thus far. On a worldwide basis, about half of HIV infections are due to the 1C subtype, which appears to be more transmissible and possibly more lethal than HIV-1B, the primary strain infecting the major-market countries.
Although HIV-1C has not yet made a major impact on the seven markets, it is impossible to predict where and when it will emerge in these nations. Therefore, in addition to the seven major markets typically discussed in a Pharmacor study, this study presents analyses of the five emerging markets of Brazil, China, India, South Africa, and Thailand. These countries were chosen for three reasons: HIV has made or will make a substantial impact on each of them; these nations represent the regions of Latin America, East Asia, South Asia, sub-Saharan Africa, and Southeast Asia, respectively, thereby permitting reasonable global coverage; and China and India embody more than 40% of the world population such that even moderate levels of HIV infection in these nations will have far-reaching implications. The overriding objective of these analyses is to determine how HIV/AIDS in the developing world will affect the global pharmaceutical industry.
Our analysis suggests that innovative approaches to pricing and new therapeutic regimens will result in substantial sales of anti-HIV agents to these countries over the 1999-2009 study period. The extent of this growth, however, will depend primarily on the degree to which these governments respond to the HIV crisis and the means by which they obtain anti-HIV therapy. We predict that didanosine (Bristol-Myers Squibb's Videx) plus hydroxyurea (Bristol-Myers Squibb's Hydrea) or lamivudine and zidovudine (Glaxo Wellcome's Combivir) with nevirapine (Boehringer Ingelheim's Viramune) will be the therapeutic interventions of choice in the developing world because of their cost-effectiveness and simplified administration schedules. Didanosine in combination with hydroxyurea is both potent and affordable, and Combivir, although lacking durability as a dual therapy, is effective when used with either a non-nucleoside reverse transcriptase inhibitor or a protease inhibitor. Didanosine and the drugs that make up Combivir are older agents that may make marketing them at reduced prices more palatable. We forecast potential sales in 2004 in the five emerging markets of $6.3 billion for Combivir and $2.9 billion for nevirapine at 10% of the current U.S. price. Didanosine could draw sales of just over $2 billion if its price point were similarly reduced.
HIV 2000--Major and Emerging Markets is part of Infectious Disease, one of six Pharmacor services that evaluate the commercial potential of drugs in research and development.
Decision Resources, Inc., is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Founded as a subsidiary of Arthur D. Little, Inc., the company has provided strategic information services for 30 years, assessing industry trends in the international health care and pharmaceutical industries.
Contact: Frank Sama, 781.487.3753 (telephone), 781.487.5750 (fax), or sama@dresources.com (e-mail). In Europe, contact Francoise Bidart, +32.2.351.4082 (telephone), +32.2.351.2347 (fax), or fbidart@decisionresources.be (e-mail). In Japan, contact Makiko Yoshimoto, +81.3.5401.2615 (telephone), +81.3.5401.2617 (fax), or makiko@bl.mmtr.or.jp (e-mail).
http://www.dresources.com SOURCE: Decision Resources, Inc.
001127
PR001126
Copyright © 2000 - PRNewswire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through PRNewswire, Permissions, 810 Seventh Ave., 32nd Floor, New York, NY 10019 http://www.prnewswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, National Library of Medicine, and donations from users like you.
Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2000. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .